Results 91 to 100 of about 29,312 (265)

Flexible Session Management in a Distributed Environment

open access: yes, 2010
Many secure communication libraries used by distributed systems, such as SSL, TLS, and Kerberos, fail to make a clear distinction between the authentication, session, and communication layers.
  +17 more
core   +2 more sources

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

open access: yesMolecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir   +12 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Constructing Committing and Leakage-Resilient Authenticated Encryption

open access: yesIACR Transactions on Symmetric Cryptology
The main goal of this work is to construct authenticated encryption (AE) hat is both committing and leakage-resilient. As a first approach for this we consider generic composition as a well-known method for constructing AE schemes.
Patrick Struck, Maximiliane Weishäupl
doaj   +1 more source

SKINNY-AEAD and SKINNY-Hash

open access: yesIACR Transactions on Symmetric Cryptology, 2020
We present the family of authenticated encryption schemes SKINNY-AEAD and the family of hashing schemes SKINNY-Hash. All of the schemes employ a member of the SKINNY family of tweakable block ciphers, which was presented at CRYPTO 2016, as the underlying
Christof Beierle   +8 more
doaj   +1 more source

Biometric-Authenticated Searchable Encryption

open access: yes, 2020
We introduce Biometric-Authenticated Keyword Search (BAKS), a novel searchable encryption scheme that relieves clients from managing cryptographic keys and relies purely on client’s biometric data for authenticated outsourcing and retrieval of files indexed by encrypted keywords.
Daniel Gardham   +2 more
openaire   +2 more sources

Encrypted Oligonucleotide Arrays for Molecular Authentication

open access: yesACS Combinatorial Science, 2019
Counterfeiting is an incredibly widespread problem, with some estimates placing its economic impact above 2% of worldwide GDP. The scale of the issue suggests that current preventive measures are either technologically insufficient or too impractical and costly to be widely adopted.
Matthew T. Holden, Lloyd M. Smith
openaire   +3 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy